Rain

Rain Oncology, Inc. is a late-stage precision oncology company developing therapies targeting oncogenic drivers, with the ability to genetically select patients it believes may benefit. This approach involves using tumor-agnostic strategies to select patients based on the underlying genetics of the tumor rather than histology. The company's lead product candidate, Milademetan, is a small-molecule MDM2 oral inhibitor, which plays an oncogenic role in multiple cancers. In addition to Milademetan, the company is also advancing a preclinical program focused on inducing synthetic lethality in cancer cells by inhibiting RAD52.